NIH director
Executive Summary
Four names have reportedly been submitted to HHS Secretary Sullivan, with current favorite choice said to be Leon Rosenberg, MD, dean of the Yale University School of Medicine. Rosenberg, 57, has been at Yale since 1965, and dean since 1984. He previously was a National Cancer Institute researcher. Other names on the list are David Korn, MD, Stanford University School of Medicine dean; Samuel Thier, MD, Institute of Medicine president; and William Danforth, MD, Washington University/St. Louis Chancellor. Danforth has repeatedly denied interest is the position, while Thier has said he is "not a candidate".
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.